Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.33 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12261426 | 0.76 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CA14CA12 | |
| SCHEMBL16440494 | 0.76 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CA14CA12 | |
| SCHEMBL20916878 | 0.75 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CA14CA12 | |
| SCHEMBL16100171 | 0.75 | CA12 (0.33) | HDAC6HDAC1HDAC2CA14CA12 | |
| SCHEMBL19492022 | 0.74 | USP30 (0.35) | HDAC6HDAC1HDAC2CA14CA12 | |
| SCHEMBL5345861 | 0.74 | AAK1 (0.35) | HDAC6HDAC1HDAC2CA14CA12 | |
| SCHEMBL1028060 | 0.74 | POLB (0.45) | HDAC6HDAC1HDAC2CA14CA12 | |
| SCHEMBL206709 | 0.73 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL22308401 | 0.73 | CA1 (0.36) | HDAC6HDAC1HDAC2CA14CA12 | |
| SCHEMBL3908694 | 0.73 | USP30 (0.35) | HDAC6HDAC1HDAC2CA14CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-03-04 | — | — | US | claimed |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-02-26 | — | — | US | claimed |
| US-6645990-B2 | For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases | AMGEN INC. | 2003-11-11 | — | — | US | claimed |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2002-12-19 | — | — | US | claimed |
| US-7196104-B2 | Thiazolyl urea compounds and methods of uses | AMGEN, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1483263-A1 | THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-03-04 | — | — | US | disclosed |
| EP-1038874-B1 | OXIME DERIVATIVES AND AGRICULTURAL CHEMICALS CONTAINING THE SAME | DAINIPPON INK & CHEMICALS (JP) | 2004-03-03 | — | — | EP | disclosed |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-02-26 | — | — | US | disclosed |
| US-6645990-B2 | For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases | AMGEN INC. | 2003-11-11 | — | — | US | disclosed |
| WO-2003070727-A1 | THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2002-12-19 | — | — | US | disclosed |
| US-6340697-B1 | PESTICIDES, PLANT DISEASE CONTROL AGENTS | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1038874-A1 | OXIME DERIVATIVES AND AGRICULTURAL CHEMICALS CONTAINING THE SAME | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2000-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | HDAC6 1381/4885HDAC1 769/4885HDAC2 2628/4885 |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | HDAC6 1381/4885HDAC1 769/4885HDAC2 2628/4885 |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | HDAC6 1381/4885HDAC1 769/4885HDAC2 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.